Preventing blood clots in diabetes by targeting specific proteins
Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes
This study is looking at how new medications that target specific proteins can help people with type 2 diabetes lower their risk of blood clots and heart problems, while also managing their blood sugar better and reducing the chance of bleeding from treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Senseion Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10972804 on NIH RePORTER |
What this research studies
This research investigates how targeting LRRC8 proteins can help prevent and treat arterial thrombosis in patients with type 2 diabetes. The approach focuses on developing new medications that not only improve blood sugar control but also reduce the risk of serious cardiovascular events like strokes and heart attacks. By understanding the role of LRRC8 in platelet function, the research aims to create safer antiplatelet therapies that minimize the risk of bleeding, a common side effect of current treatments. Patients may benefit from a novel treatment option that addresses both diabetes management and cardiovascular health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with type 2 diabetes who are at risk for cardiovascular diseases.
Not a fit: Patients without type 2 diabetes or those who do not have cardiovascular risk factors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for preventing blood clots in patients with type 2 diabetes.
How similar studies have performed: Previous research has shown promise in targeting platelet function for cardiovascular disease prevention, making this approach a potentially valuable advancement.
Where this research is happening
Saint Louis, United States
- Senseion Therapeutics, INC. — Saint Louis, United States (Active)
Researchers
- Principal investigator: Lerner, Daniel J — Senseion Therapeutics, INC.
- Study coordinator: Lerner, Daniel J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.